Translational and Clinical Research Program

转化和临床研究计划

• 批准号: 7674610
• 负责人: JEFFREY F. MOLEY
• 金额: $ 10.05万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7674610
• 关键词: Address; Award; Basic Science; Cancer Biology; Cancer Center; Caring; Cellular biology; Chemoprevention; Clinical; Clinical Research; Clinical Trials; Communities; Controlled Clinical Trials; Development; Diagnostic; Disease; Drug Industry; Environment; Focus Groups; Fostering; Goals; Grant; Health; Hematopoietic; Image; Malignant Neoplasms; Molecular; Names; Nurses; Patient Care; Phase III Clinical Trials; Physicians; Prevention; Program Research Project Grants; Psychologist; Reproduction spores; Research; Research Infrastructure; Research Personnel; Solutions; Stem cells; Structure; Testing; Therapeutic; Translational Research; Transplantation; cancer genetics; design; innovation; leukemia/lymphoma; member; multidisciplinary; novel; oncology; programs

The Siteman Cancer Center (SCC) combines excellence in clinical research, patient care and basic science to foster an environment in which novel solutions are developed for cancer-related health problems. The structure of the Translational and Clinical Research program is designed to maximize these discoveries by establishing an infrastructure for highly productive interchange between investigators in the basic science of malignancy, oncologic imaging, prevention and control and clinical trial development. During the previous three-year award period, the Translational and Clinical Research Program developed a paradigm for integrating basic science research programs with disease-oriented focus groups, producing interdisciplinary, highly translational programs that will ultimately produce multi-project grants, such as Program Project Grants (P01s) or SPOREs. This is demonstrated through the development of the newly-named Hematopoietic Development and Malignancy Program, which has united the old Stem Cell Biology Program and the Leukemia/Lymphoma/Transplant Focus Group of this program. The goals of the Translational and Clinical Research Program are as follows: ¿ To develop new translational research programs that will ultimately produce multi-project grants (such as SPOREs and P01s) through the integration of Focus Groups with the Basic Science, Prevention and Control, and Oncologic Imaging Programs. ¿ To develop, prioritize and execute novel investigator-initiated clinical trials with a particular emphasis on translational research that involves collaborators from the Basic Science, Prevention and Control, and Oncologic Imaging programs and is driven by the four central scientific themes of cancer genetics, cancer biology and development, innovative diagnostics and therapeutics, and chemoprevention. ¿ To participate in important NCI-sponsored clinical trials addressing questions that can only be answered in the setting of multi-institutional Phase III trials. ¿ To collaborate with members of the pharmaceutical industry to develop and test novel compounds that require pharmacologic and molecular expertise that can be uniquely provided by the SCC. ¿ To develop multidisciplinary clinical care and research programs that encourage contribution from all members of the oncology professional community (treating physicians, basic science researchers, psychologists, nurses, etc.).

斯特曼癌症中心 (SCC) 结合了卓越的临床研究、患者护理和基础科学，致力于培养 为癌症相关健康问题开发新解决方案的环境。的结构 转化和临床研究计划旨在通过建立一个 恶性肿瘤、肿瘤学基础科学研究人员之间高效交流的基础设施 影像、预防和控制以及临床试验开发。在上一个三年的颁奖期内， 转化和临床研究计划开发了整合基础科学研究计划的范例 与以疾病为导向的焦点小组合作，制定跨学科、高度转化的计划，最终将产生 多项目补助金，例如计划项目补助金 (P01s) 或 SPORE。这通过 制定新命名的造血发育和恶性肿瘤计划，该计划将旧的干细胞联合起来 细胞生物学项目和该项目的白血病/淋巴瘤/移植焦点小组。的目标 转化和临床研究计划如下： ¿ 开发新的转化研究计划，最终产生多项目资助（例如 SPOREs 和 P01s）通过将焦点小组与基础科学、预防和控制相结合， 和肿瘤成像项目。 ¿ 开发、优先考虑和执行由研究者发起的新型临床试验，特别强调 涉及基础科学、预防和控制领域的合作者的转化研究，以及 肿瘤成像项目由癌症遗传学、癌症等四个中心科学主题驱动 生物学和发展、创新诊断和治疗以及化学预防。 ¿ 参加 NCI 赞助的重要临床试验，解决只能在 多机构 III 期试验的设置。 ¿ 与制药行业成员合作开发和测试需要的新型化合物 SCC 可以提供独特的药理学和分子专业知识。 ¿ 制定多学科临床护理和研究计划，鼓励所有成员做出贡献 肿瘤学专业界（治疗医生、基础科学研究人员、心理学家、护士、 ETC。）。